VolitionRx (VNRX) announced the expansion of its Nu.Q Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan, to include Volition’s chemiluminescent immunoassay version of the Test via the Immunodiagnostic Systems i10 automated analyzer platform, for a new five year initial term. Previously, the agreement enabled Fujifilm Vet Systems to provide the Nu.Q Vet Cancer Test to Japanese veterinarians in the manual ELISA format. Fujifilm Vet Systems will work with Volition to perform final validation and verification of the automated platform for canine cancer screening, with the aim of launching in the summer of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX: